Home > Cardiology > HFA 2021 > SGLT2 Inhibitors in Heart Failure > Biomarker panel predicts SGLT2 inhibitor response

Biomarker panel predicts SGLT2 inhibitor response

Presented By
Dr Muthiah Vaduganathan, Brigham and Women´s Hospital, MA, USA
HFA 2021
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to lower cardiovascular (CV) risk in both patients with and without diabetes. An analysis of the CANVAS trial suggested that a biomarker assay can identify patients that benefit most from therapy. Circulating biomarkers reflecting different mechanistic pathways may offer insights into how SGLT2 inhibitors reduce CV risk. “We undertook a secondary analysis of the CANVAS trial to understand whether the use of a multimarker panel may not only identify those at highest risk but also identify patients that may benefit from SGLT2 inhibitors,” explained Dr Muthiah Vaduganathan (Brigham and Women´s Hospital, MA, USA) [1]. The CANVAS study (NCT01032629) evaluated the effect of canagliflozin compared with placebo on CV events, including CV death, heart attack, and stroke, in patients with type 2 diabete...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on